一周医药速览(02.02-02.06)

财经网
Mar 06

中国生物制药:与赛诺菲就罗伐昔替尼订立独家授权协议,交易总额超15亿美元3月4日,中国生物制药宣布,与赛诺菲就罗伐昔替尼,一款全球首创(First-in-Class)的新型、强效口服小分子JAK/ROCK抑制剂达成独家授权协议。根据协议,中国生物制药子公司正大天晴授予赛诺菲在全球范围内开发、生产及商业化罗伐昔替尼的独家许可。中国生物制药有权获得最高15.3亿美元的付款,其中包括1.35亿美元的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10